GLP-1 obesity treatment: questions to ask in 2026

GLP-1 medicines may form part of long-term obesity care for adults. They are prescription treatments, not a choice to make from a photograph, a target weight or an advertisement. Start with a discussion of your health and follow-up needs.

Preparing notes for a medical appointment
Illustration: preparing questions for a clinician.

What changed in the guidance

WHO issued its first global GLP-1 obesity guideline in December 2025. Its recommendation is conditional, reflecting limitations in long-term evidence, cost and access to care. It is not a blanket recommendation for everyone who wants to lose weight.

WHO — GLP-1 guideline, December 2025

Who should discuss treatment

The guidance addresses adults with obesity and excludes pregnant women from its recommendation. A clinician considers medical history, other medicines and pregnancy plans. Eligibility for an individual product also depends on its approved local prescribing information.

WHO — questions about GLP-1 therapies

Build a complete care plan

Food, manageable physical activity and behavioural support still matter. Agree how benefit and tolerability will be assessed and what happens if treatment is interrupted. Do not change a dose yourself or copy another person's prescription.

WHO — GLP-1 guideline, December 2025

Product safety and follow-up

WHO warns about falsified and substandard products. Use regulated prescribing and dispensing routes. Ask which symptoms need prompt attention and how to contact the care team outside normal hours. Another person's experience cannot establish safety for you.

WHO — questions about GLP-1 therapies

Your practical checklist

  • Bring a list of medicines, supplements and previous treatment attempts.
  • Discuss expected benefit, contraindications and long-term affordability.
  • Leave with a follow-up plan and instructions for possible adverse effects.

Questions and answers

Is this a quick, short course?

Not necessarily. WHO treats obesity as a chronic condition and these medicines as potentially long-term treatment. Duration and stopping plans need individual discussion.

Can an online ranking choose the right medicine?

No ranking can account for your medical history. Discuss a specific licensed medicine, its prescribing information and alternatives with your clinician.

Sources

  1. WHO — GLP-1 guideline, December 2025
  2. WHO — questions about GLP-1 therapies

Sources checked on 26 September 2026.